Novartis signs deal with Vectura to deliver generic U.S. lung therapy
Sandoz AG, a unit of Swiss pharmaceutical giant Novartis, has signed an exclusive deal with Vectura Group Plc to develop a generic version of an existing combined lung therapy for the U.S. healthcare market. Vectura, a British drug maker, has been trying to create a lung drug business since last year’s merger with Skypeharma, and has promised to “prioritise three to five generic projects each year.”
Novartis’ share price has risen by almost 20% so far this year
SOURCE: Yahoo Finance
The therapy would find a place in a $40 billion global market, and has the potential to lead to some serious payout if it “achieves some development milestones”. This would be great news for Vectura, which has struggled to gain entrance to the global respiratory market, and it could provide another strong earner for Novartis. The therapy is expected to launch sometime in the early- to mid-2020s, and would be targeted at sufferers of asthma and chronic obstructive pulmonary disease.
Vectura’s CEO, James Ward-Lilley, said: “This program represents the first partnered collaboration of this series of projects and offers substantial potential for future value creation.”
Dominion holds Novartis in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.